Anlotinib as a post-third-line therapy for the treatment of advanced nonsmall cell lung cancer

Abstract

There is no standard treatment strategy for the third-line and above treatment of advanced nonsmall cell lung cancer (NSCLC). This study aimed to investigate the effects of anlotinib in patients with NSCLC. Data was collected from a group of advanced lung cancer patients who received anlotinib as a third-line or post-third-line treatment between 2017 and 2019. The Kaplan–Meier method was used to calculate the progression-free survival (PFS) of these lung cancer patients treated with anlotinib. Univariate analysis was performed using the log-rank test. Forest plot was used for subgroup analysis.Our study included 44 patients. Oral anlotinib was used as a third-line treatment to treat 26 patients, and as a fourth-line or multiline treatment in 18 patients. The objective control rate was 5%, the disease control rate was 89%, and the median PFS was 4.0 months with a 95% confidence interval. Common toxicities included anorexia, hypertension, and fatigue. Anlotinib demonstrated promising efficacy and was well tolerated with controlled toxicity in patients with NSCLC.

Keywords:

• lung cancer
• anlotinib
• angiogenesis
• third-line
• treatment
• advanced cancer
• nonsmall cell lung cancer

Disclosure statement

The authors declare no conflict of interest.

Ethics approval and consent to participate

This study was approved by the Ethics Clerk Association of the Thoracic Department of the Brain Hospital Affiliated to Nanjing Medical University. All aspects of the study are in line with the guidelines of the Declaration of Helsinki. In this study, all patients participated voluntarily, and all patient data were strictly confidential. Because it is a retrospective study, the Ethics Committee of the Thoracic Department of the Brain Hospital Affiliated to Nanjing Medical University has specifically approved it without written consent.

Data availability statement

All data are available by contacting correspondence authors: via: [email protected]

Additional information

Funding

This work was supported by grants from the Nanjing Medical Science and Technology Development Project (No. ZKX16064).

Notes on contributors

Li Li

Li Li, PD, Department of Respiratory Medicine, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing 210029, China. The research direction is the diagnosis and treatment of lung cancer, the psychology of tumor patients, etc.

Wei Liu

Wei Liu, PD, Department of Respiratory Medicine, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing 210029, China. Research direction: Factors affecting the prognosis of lung cancer.

Yuchao Wang

Yuchao Wang, MD, Department of Respiratory Medicine, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing 210029, China. Research direction: TCM treatment of lung cancer, diagnosis and treatment of small pulmonary nodules.

Qian Zhang

Qian Zhang, PD, Department of Respiratory Medicine, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing 210029, China. Research direction: lung cancer immunotherapy, comprehensive anti-tumor therapy.

Chuanzhen Chi

Chuanzhen Chi, PD, Department of Respiratory Medicine, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing 210029, China. The research direction is the diagnosis and treatment of bronchial asthma, lung infection, lung cancer and other diseases.

Qiaohong Bai

Qiaohong Bai, PD, Department of Respiratory Medicine, The Second Hospital of Nanjing,Nanjing University of Chinese Medicine, Nanjing 210003, China. She has rich clinical experience in respiratory infectious diseases, pulmonary vascular diseases, identification of lung masses, and treatment of acute and critical respiratory diseases.

Chunhua Xu

Chunhua Xu, PD, Department of Respiratory Medicine, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing 210029, China. Director of the Endoscopy Center of the Chest Department of the Affiliated Brain Hospital of Nanjing Medical University and the Endoscopy Center of Nanjing Chest Hospital. Engaged in the clinical work of respiratory medicine for 25 years. He is good at early diagnosis and individualized comprehensive treatment of lung cancer. He has mastered respiratory endoscopic interventional diagnosis and interventional minimally invasive treatment techniques, and has accumulated rich clinical experience in the diagnosis, differential diagnosis and treatment of pulmonary nodules. experience. In recent years, he has published more than 30 SCI papers related to lung cancer and participated in the compilation of a monograph.

Rusong Yang

Rusong Yang, MD, Department of Thoracic Surgery, the Affiliated Nanjing Brain Hospital of Nanjing Medical University, Nanjing 210029, China. Chief physician, doctoral tutor. Carrying out diagnosis and treatment of lung nodules for 12 years, he has advanced knowledge in the diagnosis of lung nodules, and accurately diagnosed tens of thousands of lung nodules, most of which have been verified by surgical pathological results. Continue to sum up experience and data, and practice the magical "eye-eyed golden eye". The operation is characterized by single-port thoracoscopy, which is precise, standardized, thorough, and extremely minimally invasive. Part-time recipient of Jiangsu Provincial Government Scholarship for Studying Abroad. Published nearly 50 papers as the first author or corresponding author, of which 21 were collected by SCI; received 5 provincial and municipal science and technology progress awards and new technology introduction awards.